Atria Wealth Solutions Inc. Boosts Stake in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Atria Wealth Solutions Inc. increased its holdings in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 10.5% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 11,692 shares of the biotechnology company’s stock after acquiring an additional 1,108 shares during the period. Atria Wealth Solutions Inc.’s holdings in Sarepta Therapeutics were worth $1,422,000 as of its most recent SEC filing.

Other large investors have also recently bought and sold shares of the company. CIBC Asset Management Inc boosted its position in Sarepta Therapeutics by 3.3% during the third quarter. CIBC Asset Management Inc now owns 2,712 shares of the biotechnology company’s stock worth $339,000 after purchasing an additional 86 shares in the last quarter. Louisiana State Employees Retirement System lifted its stake in Sarepta Therapeutics by 0.4% in the 4th quarter. Louisiana State Employees Retirement System now owns 26,500 shares of the biotechnology company’s stock valued at $3,222,000 after buying an additional 100 shares in the last quarter. Manchester Capital Management LLC grew its holdings in Sarepta Therapeutics by 86.6% during the 4th quarter. Manchester Capital Management LLC now owns 237 shares of the biotechnology company’s stock valued at $29,000 after buying an additional 110 shares during the last quarter. UMB Bank n.a. increased its position in Sarepta Therapeutics by 36.0% during the fourth quarter. UMB Bank n.a. now owns 521 shares of the biotechnology company’s stock worth $63,000 after buying an additional 138 shares in the last quarter. Finally, Oppenheimer Asset Management Inc. raised its holdings in shares of Sarepta Therapeutics by 3.4% in the third quarter. Oppenheimer Asset Management Inc. now owns 4,457 shares of the biotechnology company’s stock worth $557,000 after acquiring an additional 145 shares during the last quarter. Hedge funds and other institutional investors own 86.68% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms recently commented on SRPT. Deutsche Bank Aktiengesellschaft started coverage on Sarepta Therapeutics in a research report on Tuesday, February 11th. They set a “hold” rating and a $136.00 price objective for the company. Piper Sandler lowered their price target on shares of Sarepta Therapeutics from $200.00 to $182.00 and set an “overweight” rating for the company in a report on Wednesday, November 27th. Evercore ISI reduced their price objective on shares of Sarepta Therapeutics from $179.00 to $170.00 and set an “outperform” rating on the stock in a research note on Thursday, November 7th. Robert W. Baird decreased their target price on shares of Sarepta Therapeutics from $200.00 to $193.00 and set an “outperform” rating on the stock in a research report on Thursday, November 7th. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $202.00 price target on shares of Sarepta Therapeutics in a report on Monday, January 27th. One research analyst has rated the stock with a sell rating, three have given a hold rating, nineteen have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $176.77.

Insider Activity

In other news, Director Hans Lennart Rudolf Wigzell sold 10,500 shares of the stock in a transaction dated Thursday, December 12th. The stock was sold at an average price of $124.84, for a total value of $1,310,820.00. Following the completion of the sale, the director now owns 22,840 shares in the company, valued at approximately $2,851,345.60. This trade represents a 31.49 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Kathryn Jean Boor sold 1,636 shares of the business’s stock in a transaction that occurred on Thursday, December 5th. The stock was sold at an average price of $125.55, for a total value of $205,399.80. Following the transaction, the director now directly owns 5,880 shares in the company, valued at $738,234. This trade represents a 21.77 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 7.70% of the company’s stock.

Sarepta Therapeutics Trading Down 2.0 %

Shares of SRPT stock opened at $106.28 on Monday. The company has a quick ratio of 3.03, a current ratio of 3.84 and a debt-to-equity ratio of 0.93. Sarepta Therapeutics, Inc. has a fifty-two week low of $101.15 and a fifty-two week high of $173.25. The firm’s 50 day moving average price is $117.54 and its two-hundred day moving average price is $123.36. The stock has a market cap of $10.15 billion, a price-to-earnings ratio of 85.02 and a beta of 0.75.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.